
LY2452473
Also known as OPK-88004, an experimental SARM used in clinical trials.
Overview
LY2452473 (OPK-88004) is a selective SARM with dual agonist-antagonist activity: anabolic in muscle/bone and suppressive in prostate. It mimics testosterone benefits, improving muscle mass, strength, bone formation, and hormonal balance with low side effects. Ideal for sports nutrition, prostate health, and muscle recovery formulations.
Synonyms: LY-900010; TT-701/Tadalafil; LY-2452473/Tadalafil; TT-701 and Tadalafil; LY-2452473 and Tadalafil; Tadalafil/LY-2452473; Tadalafil and TT-701; LY-2452473
Product Categories: SARM series
Mol File: 1029692-15-6.mol
Physicochemical Properties
Boiling point: 617.6±55.0°C(Predicted)
Density: 1.28±0.1g/cm3(Predicted)
Storage temp.: Store at -20°C
Solubility: Acetonitrile (Slightly), Methanol (Slightly)
Form: Solid
Color: White to Off-White
MSDS Information
Experimental Data
1.Cell Experiment
Solubility in DMSO: 62.5 mg/mL (166.92 mM; solubilized with ultrasound; the solubility of the product is significantly affected by hygroscopic DMSO, so please use freshly opened DMSO)
Preparing Stock Solutions:

Please choose a suitable solvent to prepare the stock solution based on the product's solubility in different solvents. Once the solution is prepared, aliquot and store it to avoid product degradation caused by repeated freeze-thaw cycles.
Storage conditions and shelf life of the stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, use within 2 years; when stored at -20°C, use within 1 year.
2.Animal Experiment
Please choose the appropriate dissolution method based on your experimental animals and administration route.
For all of the following dissolution schemes, please first prepare a clear stock solution according to the In Vitro method, and then add solubilizing agents in sequence:
— To ensure the reliability of experimental results, the clear stock solution can be appropriately stored according to storage conditions; for in vivo experiment working solutions, it is recommended to prepare them fresh and use them on the same day.
The percentages shown before the following solvents refer to the volume ratio of that solvent in the final solution you prepare. If precipitation or crystallization occurs during preparation, solubilization can be assisted by heating and/or sonication.
Protocol 1
Please add each solvent in order: 10% DMSO, 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (5.55 mM); clear solution
This method can obtain a clear solution with ≥ 2.08 mg/mL (saturation unknown).
For 1 mL of working solution, take 100 μL of 20.8 mg/mL clear DMSO stock solution and add it to 900 μL of 20% SBE-β-CD saline solution, then mix thoroughly.
Dissolve 2 g of SBE-β-CD (sulfobutyl ether β-cyclodextrin) powder in 10 mL of saline, fully dissolving to a clear and transparent solution.
Protocol 2
Please add each solvent in order: 10% DMSO, 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.55 mM); clear solution
This method can obtain a clear solution with ≥ 2.08 mg/mL (saturation unknown). For animal experiments lasting more than half a month, use this method as appropriate.
For 1 mL of working solution, take 100 μL of 20.8 mg/mL clear DMSO stock solution and add it to 900 μL of corn oil, then mix well.
Pharmacodynamics
Mechanism Of Action
Similar Products

AC-262536
Therapy
: Musculoskeletal diseases
Target
:
CAS
: 870888-46-3
MF
: C18H18N2O
MW
: 278.36

AC-262,356
Therapy
: Musculoskeletal diseases
Target
:
CAS
: 871032-12-1
MF
: C18H18N2O
MW
: 278.36

PF-06260414
Therapy
: Musculoskeletal diseases
Target
: Opioid receptors
CAS
: 1612755-71-1
MF
: C14H14N4O2S
MW
: 302.35

GSK-2881078
Therapy
: Musculoskeletal diseases
Target
: AR
CAS
: 1539314-06-1
MF
: C14H13F3N2O2S
MW
: 330.33
